Limited coverage drugs – sacubitril-valsartan

sacubitril-valsartan

24 mg/26 mg, 49 mg/51 mg, 97 mg/103 mg tablet

For the treatment of heart failure (HF) with reduced ejection fraction in patients with New York Heart Association (NYHA) class II or III HF, if ALL the following clinical criteria are met:

• Reduced left ventricular ejection fraction (LVEF) ≤ 40%

AND

• Patient has NYHA class II to III symptoms despite at least four weeks of treatment at the optimum stable dose of:
  • an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin II receptor antagonist (ARB), and
  • a beta blocker

AND

• Patient will be using sacubitril-valsartan in combination with other recommended therapies, including an aldosterone antagonist (if tolerable)

AND

• Initiation and up-titration should be conducted by a prescriber experienced with the treatment of heart failure

Indefinite